HK1084034A1 - Eye-drop vaccine containing copolymer 1 for therapeutic immunization - Google Patents
Eye-drop vaccine containing copolymer 1 for therapeutic immunizationInfo
- Publication number
- HK1084034A1 HK1084034A1 HK06104409.1A HK06104409A HK1084034A1 HK 1084034 A1 HK1084034 A1 HK 1084034A1 HK 06104409 A HK06104409 A HK 06104409A HK 1084034 A1 HK1084034 A1 HK 1084034A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cns
- eye
- copolymer
- pns
- injury
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43831003P | 2003-01-07 | 2003-01-07 | |
PCT/IL2004/000006 WO2004060265A2 (en) | 2003-01-07 | 2004-01-06 | Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1084034A1 true HK1084034A1 (en) | 2006-07-21 |
Family
ID=32713312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06104409.1A HK1084034A1 (en) | 2003-01-07 | 2006-04-11 | Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
Country Status (12)
Country | Link |
---|---|
US (2) | US20070248569A1 (ja) |
EP (1) | EP1583506B1 (ja) |
JP (1) | JP5291878B2 (ja) |
CN (2) | CN1758922A (ja) |
AT (1) | ATE548045T1 (ja) |
AU (1) | AU2004203772B2 (ja) |
CA (1) | CA2512735C (ja) |
ES (1) | ES2386435T3 (ja) |
HK (1) | HK1084034A1 (ja) |
IL (1) | IL169552A (ja) |
MX (1) | MXPA05007329A (ja) |
WO (1) | WO2004060265A2 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9089509B2 (en) * | 2006-06-28 | 2015-07-28 | Yeda Research And Development Co., Ltd. | Method of treatment of age-related macular degeneration |
EP2195008A1 (en) | 2007-09-24 | 2010-06-16 | Hadasit Medical Research Services & Development Ltd. | Use of copolymer 1 for treatment of muscular dystrophy |
US8697046B2 (en) | 2008-08-15 | 2014-04-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of administering interferon gamma to absorb fluid from the subretinal space |
NZ599899A (en) | 2009-11-10 | 2014-10-31 | Allegro Pharmaceuticals Inc | Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites |
US11673914B2 (en) | 2009-11-10 | 2023-06-13 | Allegro Pharmaceuticals, LLC | Peptide therapies for reduction of macular thickening |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
NZ609938A (en) | 2010-10-11 | 2015-11-27 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
EP2699317B1 (en) | 2011-04-21 | 2016-08-10 | Mapi Pharma Limited | Random pentapolymer for treatment of autoimmune diseases |
US8815511B2 (en) | 2011-10-10 | 2014-08-26 | Teva Pharmaceutical Industries, Ltd. | Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate |
US9611314B2 (en) | 2013-09-13 | 2017-04-04 | The Penn State Research Foundation | Functional peptide analogs of PEDF |
CN106491614A (zh) * | 2016-12-06 | 2017-03-15 | 郑州郑先医药科技有限公司 | 一种用于治疗脊髓损伤的西药组合及用途 |
WO2018136669A2 (en) * | 2017-01-19 | 2018-07-26 | Allegro Phamaceuticals, Inc. | Therapeutic and neuroprotective peptides |
EP3600553A4 (en) | 2017-03-26 | 2020-09-02 | Mapi Pharma Ltd. | GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS |
WO2019173361A2 (en) * | 2018-03-05 | 2019-09-12 | The Schepens Eye Research Institute, Inc. | A therapy for glaucoma and optic neuropathy by targeting colony stimulating factors |
WO2021222913A1 (en) * | 2020-04-30 | 2021-11-04 | Koziol Jeffrey E | Micro dosing of viral vaccines |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4525589A (en) | 1988-10-27 | 1990-05-14 | Regents Of The University Of Minnesota | Liposome immunoadjuvants containing il-2 |
IL104382A0 (en) | 1992-01-17 | 1993-05-13 | Solvay Animal Health Inc | Vaccine containing acemannan as an adjuvant |
US5571515A (en) * | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
US6153182A (en) * | 1997-12-19 | 2000-11-28 | Uab Research Foundation | Lymphotactin as an adjuvant |
CA2320044A1 (en) * | 1998-02-13 | 1999-08-19 | Ruth Maron | Treatment of multiple sclerosis using cop-1 and th2-enhancing cytokines |
US6616925B1 (en) * | 1998-04-02 | 2003-09-09 | I.D.M. Immuno-Designed Molecules | Combined preparation for the treatment of neoplasic diseases or of infectious diseases |
JP2003517452A (ja) * | 1999-02-05 | 2003-05-27 | アルク−アベル・アー/エス | 新規粘膜デリバリーシステム |
CA2382652A1 (en) * | 1999-08-24 | 2001-03-01 | Teva Pharmaceutical Industries, Ltd. | A vaccine composition and method of using the same |
WO2001052878A2 (en) * | 2000-01-20 | 2001-07-26 | Yeda Research And Development Co. Ltd. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
US20020037848A1 (en) | 2000-06-07 | 2002-03-28 | Michal Eisenbach-Schwartz | Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
SI1429800T1 (sl) * | 2001-12-06 | 2009-08-31 | Yeda Res & Dev | Cepivo in njegova uporaba za zdravljenje amiotrofiäśne lateralne skleroze |
WO2005030955A1 (ja) * | 2003-09-29 | 2005-04-07 | Chugai Seiyaku Kabushiki Kaisha | Nk細胞に発現するタンパク質 |
JP4501562B2 (ja) | 2004-07-09 | 2010-07-14 | 旭硝子株式会社 | 積層膜付き基材およびその製造方法 |
-
2004
- 2004-01-06 CN CNA2004800062290A patent/CN1758922A/zh active Pending
- 2004-01-06 EP EP04700289A patent/EP1583506B1/en not_active Expired - Lifetime
- 2004-01-06 CA CA2512735A patent/CA2512735C/en not_active Expired - Fee Related
- 2004-01-06 WO PCT/IL2004/000006 patent/WO2004060265A2/en active Application Filing
- 2004-01-06 AT AT04700289T patent/ATE548045T1/de active
- 2004-01-06 MX MXPA05007329A patent/MXPA05007329A/es active IP Right Grant
- 2004-01-06 US US10/541,492 patent/US20070248569A1/en not_active Abandoned
- 2004-01-06 ES ES04700289T patent/ES2386435T3/es not_active Expired - Lifetime
- 2004-01-06 CN CN201110438909.1A patent/CN102580069B/zh not_active Expired - Fee Related
- 2004-01-06 AU AU2004203772A patent/AU2004203772B2/en not_active Ceased
- 2004-01-06 JP JP2006500369A patent/JP5291878B2/ja not_active Expired - Fee Related
-
2005
- 2005-07-06 IL IL169552A patent/IL169552A/en active IP Right Grant
-
2006
- 2006-04-11 HK HK06104409.1A patent/HK1084034A1/xx not_active IP Right Cessation
-
2009
- 2009-05-07 US US12/437,167 patent/US8895501B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN102580069B (zh) | 2015-09-30 |
CA2512735C (en) | 2016-03-08 |
AU2004203772A1 (en) | 2004-07-22 |
WO2004060265A2 (en) | 2004-07-22 |
US20090214470A1 (en) | 2009-08-27 |
AU2004203772B2 (en) | 2009-07-16 |
ATE548045T1 (de) | 2012-03-15 |
US8895501B2 (en) | 2014-11-25 |
CN1758922A (zh) | 2006-04-12 |
WO2004060265A3 (en) | 2005-09-22 |
EP1583506A2 (en) | 2005-10-12 |
IL169552A (en) | 2012-05-31 |
CA2512735A1 (en) | 2004-07-22 |
ES2386435T3 (es) | 2012-08-21 |
JP2006515870A (ja) | 2006-06-08 |
EP1583506A4 (en) | 2009-01-07 |
MXPA05007329A (es) | 2005-09-30 |
CN102580069A (zh) | 2012-07-18 |
EP1583506B1 (en) | 2012-03-07 |
US20070248569A1 (en) | 2007-10-25 |
JP5291878B2 (ja) | 2013-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1084034A1 (en) | Eye-drop vaccine containing copolymer 1 for therapeutic immunization | |
HK1058892A1 (en) | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith in protecting cns cells from glutamate toxicity | |
CY1123341T1 (el) | Μη επιλεκτικο καναλι κατιοντων στα νευρωνικα κυτταρα και ενωσεις που μπλοκαρουν το καναλι για χρηση στη θεραπευτικη αντιμετωπιση της εγκεφαλικης εξοιδησης | |
HK1064951A1 (en) | Use of poly-glu, tyr for neuroprotection therapy of the cns or pns poly-glu | |
TW200509958A (en) | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | |
WO2006037106A3 (en) | Carboxy-amido-triazoles for the localized treatment of ocular diseases | |
DK1248643T3 (da) | Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi | |
ES2149888T3 (es) | 3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias. | |
PE41395A1 (es) | Antagonista de taquiquinina no peptidico | |
BR0200283A (pt) | Composições farmacêuticas para o tratamento de distúrbios do snc e de outros distúrbios | |
ATE251672T1 (de) | Hsv stamm mit mangel für funktionelle icp27 und icp34.5 genen | |
WO2003015713A3 (en) | Treatment of glial tumors with glutamate antagonists | |
MXPA03005721A (es) | Uso novedoso de artemina, un miembro de la familia de ligandos gdnf. | |
SI1456380T1 (sl) | Smad inhibitorji za zdravljenje cns bolezni | |
EP0932613A4 (en) | EXPRESSION BLOCKING OF VIRULENT FACTORS IN S. AUREUS | |
IS8162A (is) | Aðferð til að meðhöndla eða fyrirbyggja neðri þvagvegaeinkenni | |
BRPI0411864A (pt) | combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas | |
WO2002062777A3 (en) | Amino ceramide-like compounds and therapeutic methods of use | |
WO2003105750A3 (en) | ANTIGEN PRESENTER CELLS FOR NEUROPROTECTION AND NERVOUS REGENERATION | |
BG103687A (en) | Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative processes and conditions related to the central nervous system | |
WO2004060266A3 (en) | Eye-drop vaccine containing copolymer poly-ye for therapeutic immunization | |
UA87982C2 (ru) | Способ лечения или предотвращения расстройств центральной нервной системы производными 1-ар(алк)-4-пиперидиноимидазолин-2-она, фармацевтическая композиция | |
WO2002099069A3 (en) | Modulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule | |
HUP0302330A2 (hu) | Praziquanteltartalmú készítmények sarcocystis, neospora, toxoplasma és isospora által okozott betegségek kezelésére | |
WO2002083060A3 (en) | Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210103 |